Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pure manipulation by the MM's looking at the tiny trading action so far today. Should be made illegal once and for all. Oxygen thieves those responsible.
A very nice green day. Up 10% from Friday's close. Better than a knee in the bollocks.
Regardless of the current uncertainty surrounding crypto at the Fed level in the US, (i) SHIB is global, and (ii) SHIB is positioned for greatness moving forward by popular opinion.
Why do YOU want SHIB and holders to fail so badly? We assume you lost all of your pocket money on SHIB at some point. Aww...perhaps have a nice cup of cocoa to help squish some of that bitterness, sweetheart. LOL jog on.
sorry to hear. Is it trading again now on yours? Whatever Khiron's current and future looks like (and it certainly looked damn good in LATAM), I am confident that CEO Alvaro is working hard to make this a success. This is my sense anyhow. GL to all us investors.
Yes I am still an investor. Holding a bag at a significant paper loss but this was always a long term investment for me. Encouraged by your update / their current status and think anyone new to Blueberries considering buying at this crazy low share price is very fortunate indeed.
I am not seeing any evidence I'm afraid. I lost quite a bit holding this crap 'investment'.
Agreed. Been holding a very loaded position for a while now.
News / announcements could drop any day. We would think that potential deals involving Revive's (patented) "Bucillamine" are being discussed in parallel with the FDA process. Plus we should remember that Bucillamine is not only a potential treatment for Covid symptoms but also proven to be very effective for Rheumatoid Arthritis for example. If the FDA does not swing our way for a Covid treatment after all, this whole process has at least significantly increased exposure for, and the knowledge of, Bucillamine on the big stage.
Whales will buy back in soon IMO. Imagine the colossal losses they take during these temporary dips / crashes..
Bought a Billion down here.
Loading SHIB & DOGE big time. Thanks for all your informative posts, Rick.
A very encouraging rise in PPS today for sure. Excited for this continuation.
Wow it is BUY TIME for me personally. Selling some other stocks then am backing up the truck.
#Khiron
All of Crypto is down big today because the SEC are on Binance's back again. If SHIB hits below .7 I am adding another billion personally.
OMG LOL! Wrong yet again. And if you really believe the FDA merely handed Revive this opportunity without doing any due diligence of their own then in fact you are the deluded, clueless one.
The two are joined for now however, most of us invested in Revive’s Bucillamine not in Michael Frank per se.
Bet you don’t even know what Bucillamine is and represents. Too much technical detail for $7 postings isn’t it.
Enjoy the dreary basement couch life, sweetheart..and “ciao” for now from Las Vegas!!
Revive progressing to an FDA Phase III trial is no mean feat. What have you achieved? ..<crickets>..Thought so.
Revive's Bucillamine is still by far one the best opportunities across the dire OTCM at present. At this stage of their trials (and related FDA & industry exposure) plus the current low share price, the risk/reward is well worth me continuing taking personally.
I believe in Revive's Bucillamine. Now sell me your cheap shares and good luck!
Interesting and encouraging. Thank you for the update.
No cliff here yet. Just in your own head.
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
– Preclinical data in ASD model demonstrate prosocial effects of MM-402 –
NEW YORK, May 24, 2023 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced announced today the upcoming presentation of preclinical data of MM-402, the Company’s proprietary form of the R-enantiomer of 3,4-Methylenedioxymethamphetamine (“MDMA”), in a model for autism spectrum disorder (“ASD”) at the ASCP 2023 Annual Meeting that is being held in Miami Beach, FL from May 30-June 2, 2023. The Company plans to initiate its first clinical trial of MM-402 in 2023.
The late-breaking poster entitled “MM-402, R(-)-3,4-Methylenedioxymethamphetamine, Demonstrates Prosocial and Therapeutic-Like Effects in Fmr1 Knockout Mice, a Preclinical Model of Autism Spectrum Disorder (due to Fragile X syndrome),” will be presented on Wednesday, May 31, 2023 at 11:15 am ET. This study demonstrated that administration of MM-402 increased social interaction in a characterized preclinical model of ASD. MM-402 exhibited a robust effect on social interaction and was more potent than racemic MDMA with reduced hyperactivity effects.
“We are very pleased with these promising preclinical data, which provide the first evidence of prosocial activity of MM-402 in an ASD model and support the potential applications to enhancing social functioning in individuals with ASD,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “Importantly, MM-402 was able to achieve increased social interaction without the level of hyperactivity seen with racemic MDMA. With even further preclinical evidence to support our approach, we are extremely excited to initiate our Phase 1 clinical trial of MM-402 later this year.”
In addition to MindMed’s preclinical research program for MM-402, MindMed’s collaborators at University Hospital Basel (“UHB”) in Switzerland are currently enrolling participants in a Phase 1 investigator-initiated trial of R-MDMA, S-MDMA and R/S-MDMA in healthy volunteers. The Phase 1 trial is a randomized, placebo-controlled, double-blind, 5-period crossover study. The trial plans to enroll 24 healthy subjects, who will each receive doses of R-MDMA (125 and 250 mg), S-MDMA (125 mg), MDMA (125 mg), and placebo. Acute subjective effects in this study are being assessed using the Visual Analog Scales (“VAS”) and the 5 Dimensions of Altered States of Consciousness (“5D-ASC”) along with measurement of autonomic, endocrine and mood effects, among others. Additional information about this trial is available on our website (mindmed.co) and on clinicaltrials.gov (identifier: NCT05277636).
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
Contacts
For Media & Investor Inquiries, please contact:
Maxim Jacobs, CFA
Vice President, Investor Relations and Corporate Communications
Mind Medicine (MindMed) Inc.
ir@mindmed.co
media@mindmed.co
Bought one Billion. Holding all. Patient.
Bought 100k. Holding all.
Patronizing little peasant aren't you? You misinterpreted my original post of course. Jog on, sad act.
I think it is clear I am not a Michael Frank fan but you are being a dick today with your posts content. We are all hurting and furious so have a bit of class eh.
This is an interesting turnaround.
Effective DD suggests this investment might work out.
You, however, will not (based on your turd posts).
Best advice is you shuffle back to your Stepdaddy’s basement couch and focus on your acne, son.
Sack of crap PPS despite the company fundamentals seemingly operating fine..
Not convinced I agree. Assuming they manufacture and sell effectively, they should generate serious incremental revenue. The rest will follow. We are in super early IMO.
I personally believe we buyers here are in for a highly lucrative surprise if patient. I might be wrong of course so don’t go off of me.
What’s going on now? On the road but just saw the POSSP..
There was a decent YouTube video interviewing CEO Barrow a few days ago. The Dales Report from memory. I was left more encouraged overall. Plus Barrie has cleaned up his appearance i.e. now clean cut professional look vs wannabe hippy (which is appropriate in the grand scheme).
1000% agree DOGE will soar big - therefore am buying & holding, regularly.
Flipping is for the backyard BBQ.
Same for SHIB. Owning both is the best strategy IMO.
SBFM - Cancer Curers or Con Artists? I hoped the former. They must be formally investigated to prove which applies.
#losingafortune
Elon will not allow DOGE to not succeed. He would lose face at this point and he has too much influence / power which enables him to avoid losing face in the vast majority of respects.
Buying all I can.
Big future value IMO.
Personally I now think of MF as the big letdown. Until he proves otherwise.
It is no good owning the best thoroughbred race horse if the Jockey is crap.
I reckon we'd hear a louder pop from an ant's underpants than this POS stock.
One of my worst ever investments too. Appalled by the CEO Chris Bunka's compensation history against a severe lack of performance.
@Slojab, could you please share the details of your SEC related comment either here or by DM to me. I have a few additional OTCM companies that should be 100% be formally investigated. Thanks in advance.
Thanks for sharing. Perhaps this might lead to "getting back" some of the substantial losses many of us incurred to date connected to Roger Pawson's running / controlling of the company. We wait.